UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers. The company's mission is to elevate treatment options for individuals living with urological cancers, aiming to transform the existing paradigm in uro-oncology by prioritizing patient needs. UroGen Pharma's primary headquarters are located in Princeton, New Jersey, United States, with additional operations in Israel.

Central to UroGen Pharma's portfolio is its proprietary RTGel® reverse-thermal hydrogel technology, a sustained-release platform designed to enable longer exposure of urinary tract tissue to medications, thereby enhancing treatment efficacy. The company has two FDA-approved products: JELMYTO® (mitomycin) for pyelocalyceal solution, approved in April 2020 for low-grade upper tract urothelial cancer (LG-UTUC), and ZUSDURI™ (mitomycin) for intravesical solution, approved in June 2025 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Its pipeline includes UGN-102 (under FDA review for LG-IR-NMIBC), UGN-103 (a next-generation formulation for LG-IR-NMIBC with positive Phase 3 data), UGN-104 (for LG-UTUC), and UGN-501 (an investigational oncolytic virus for high-grade non-muscle invasive bladder cancer).

Led by President and CEO Liz Barrett, appointed in January 2019, UroGen Pharma continues to advance its market position in the biotechnology sector. Recent developments include reporting full-year 2025 revenue of $109.8 million and Q4 2025 revenue of $37.84 million. The company also saw the permanent J Code for ZUSDURI™ become effective in January 2026, facilitating patient access, and published positive 24-month duration of response data for ZUSDURI™ from the ENVISION trial in March 2026.